Partners

PharmacoFore internally created all of its lead compounds and product candidates and works diligently to protect intellectual property assets. In an effort to further develop our lead compounds, we aim to collaborate with global companies to accelerate the development and commercialization of our products. Our extensive patent portfolio covers compositions-of-matter, methods-of-use, pharmaceutical formulations, and manufacturing processes.

We are currently seeking partners for multiple programs:

• PF0713 Sedative-Hypnotic (human proof-of-concept – hPOC – achieved)

• Pain
  • Moderate-to-Severe
    • Bio-Activated Molecular Delivery™ Systems and MPAR™ Technology for Abuse-Resistant Opioids
      • PF03: Morphones
        • Hydromorphone (hPOC achieved for hydromorphone Bio-MD™ system)
        • Oxymorphone
        • Morphine
      • PF06: Codones
        • Oxycodone (advanced into development)
        • Hydrocodone
      • PF16: Tapentadol
  • PF05 Reduced Opioid-Associated Side Effects (including OIC) 
• PF0713 Antiemetic 
• PF08 Attention Deficit Hyperactivity Disorder (ADHD)
  • Bio-MD Systems and MPAR Technology for Abuse-Resistant Amphetamine